New Real-World Insights into IL-17 Inhibitor Performance for Special-Site Psoriasis

Psoriasis affecting anatomically sensitive or difficult-to-treat areas—such as the scalp, face, intertriginous regions, nails, palms and soles, and genital skin—can present unique clinical challenges. Even when overall body surface area (BSA) involvement is limited, disease in these sites can cause significant symptoms, psychosocial burden, and functional impairment.

“Consequently, patients with special-site involvement often experience treatment resistance and require systemic therapies despite relatively limited body surface area involvement,” the study authors added.¹

Biologic therapies targeting the interleukin-17 (IL-17) pathway have demonstrated high efficacy in randomized clinical trials; however, real-world outcomes in patients with predominant special-site involvement remain less well characterized. A recent large real-world cohort study sought to evaluate the effectiveness and safety of IL-17 inhibitors in this population and identify clinical predictors associated with achieving meaningful treatment responses.²

Study Design

Investigators conducted a retrospective observational study using data from the China Psoriasis Standardized Diagnosis and Treatment Center registry, a multicenter database collecting clinical information on patients receiving psoriasis care. The analysis included 1,469 adult patients with plaque psoriasis involving at least 1 special site who initiated treatment with an IL-17 inhibitor (secukinumab, ixekizumab, or brodalumab) between June 2020 and September 2025. Eligible participants were required to have complete baseline and week-12 follow-up data. Individuals receiving other biologics or systemic immunosuppressants concurrently were excluded.

Disease severity was assessed using several standardized metrics: Psoriasis Area and Severity Index (PASI), Investigator’s Global Assessment (IGA), body surface area involvement (BSA), and the Dermatology Life Quality Index (DLQI). The primary outcomes were achievement of PASI75 (≥75% improvement in PASI) and PASI90 (≥90% improvement) after 12 weeks of treatment.

The study cohort was predominantly male (71.1%) with a median age of 43 years. At baseline, the median PASI score was 6.4 and the median BSA involvement was 9%, while the median DLQI was 8. Most patients had previously received topical therapies (77.9%), and more than half had used traditional systemic treatments.

Trial Results

After 12 weeks of IL-17 inhibitor therapy, significant improvements were observed across all disease severity and quality-of-life measures. Median PASI scores decreased from 6.4 at baseline to 1.0, representing an 84% reduction. Median BSA decreased from 9% to 1.5%. Similar improvements were seen in IGA scores and DLQI, with median DLQI decreasing from 8 to 1, indicating substantial improvements in patient-reported quality of life.

In terms of treatment response rates, 74.0% of patients achieved PASI50, while 58.6% achieved PASI75 and 41.5% achieved PASI90 at week 12. Although these outcomes demonstrate meaningful clinical benefit, the response rates were somewhat lower than those reported in randomized clinical trials of IL-17 inhibitors. Investigators noted that this difference may reflect real-world patient heterogeneity, differences in baseline disease characteristics, and the particular challenges associated with treating psoriasis in special anatomical locations.

The safety profile observed in the cohort was favorable. Only 11 adverse events (0.75%) were reported among the 1,469 patients during the 12-week follow-up period. Most events were mild or moderate in severity, with only one severe adverse event documented. No major safety concerns emerged, reinforcing the generally favorable tolerability profile of IL-17 inhibitors observed in clinical trials and post-marketing studies.

Further Analysis

Beyond evaluating overall treatment outcomes, the investigators aimed to identify factors associated with treatment response. For PASI75 response, independent predictors included BMI, baseline DLQI, baseline BSA, and baseline IGA. Lower BMI was associated with a greater likelihood of achieving treatment response, consistent with prior observations that obesity may reduce biologic treatment effectiveness, possibly through pharmacokinetic factors or obesity-related inflammatory pathways. Higher baseline DLQI and greater BSA involvement were also associated with increased likelihood of reaching PASI75, suggesting that patients with greater baseline disease burden or quality-of-life impairment may have greater potential for measurable improvement.

Similar predictors were identified for achieving PASI90 response. Lower BMI, higher baseline DLQI, greater BSA involvement, and baseline IGA score were again significant factors. In addition, employment status emerged as an independent predictor for achieving PASI90, indicating that certain socioeconomic factors may influence treatment outcomes. While the mechanism underlying this association remains unclear, investigators suggested that employment status may correlate with factors such as treatment adherence, access to care, or psychosocial stressors.

Using these predictors, researchers developed clinical nomograms designed to estimate the probability of achieving PASI75 or PASI90 responses in individual patients. The predictive models demonstrated moderate discriminative ability, with area under the curve (AUC) values of approximately 0.62 to 0.64. Although not highly precise, these models may help clinicians integrate multiple baseline factors when considering treatment expectations and therapeutic decision-making.

For clinicians, nurse practitioners, and physician assistants involved in psoriasis management, the results underscore the importance of assessing baseline disease burden, patient BMI, and quality-of-life impact when evaluating treatment strategies. Recognizing factors that may influence treatment response could help guide therapeutic selection and support more individualized care.

References

1. Billi AC, Gudjonsson JE, Voorhees JJ. Psoriasis: Past, Present, and Future. J Invest Dermatol. 2019;139(11):e133-e142. doi:10.1016/j.jid.2019.08.437

2. Hu F, Xiong X, Lai Y, Tao X, Zhang L. Clinical characteristics, effectiveness, safety, and predictors of PASI75/90 responses to IL-17 biologics in psoriasis involving special sites: a large real-world cohort study revealing treatment response heterogeneity. J Dermatolog Treat. 2026;37(1):2633794. doi:10.1080/09546634.2026.2633794